Amanda R. McFee Winans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda R. McFee Winans has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alvin B. Oung
Department of Pharmacy Practice University of Wyoming School of Pharmacy Laramie Wyoming USA
1 shared publication - Anne R. Ottney
Department of Pharmacy Practice Ferris State University Big Rapids Michigan USA
1 shared publication - Jeffrey Bratberg
Clinical Professor, University of Rhode Island, Kingston, RI
1 shared publication - Jennie B. Jarrett
University of Illinois Chicago College of Pharmacy
1 shared publication - Lindsay M. Arnold
Department of Pharmacy, Boston Medical Center, Boston, Massachusetts, USA
1 shared publication - Lucas G. Hill
University of Pittsburgh School of Pharmacy, PA, USA
1 shared publication
Latest Publications
- 3 February 2022
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 5 (2) , 114-117
Call to action: Clinical pharmacy and addressing the opioid crisis
- 3 February 2022
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 5 (2) , 114-117
Call to action: Clinical pharmacy and addressing the opioid crisis
- 6 October 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (8) , 1493-1513
Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy
The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence‐based opioid stewardship and harm reduction practices, contribute to the medical management of opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far‐reaching pharmacist‐led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence‐based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high‐level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist‐led clinical services, so that resources can be allocated effectively.
- 6 October 2020
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 3 (8) , 1493-1513
Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy
The opioid crisis represents one of the largest failures of our current health care system as it continues to claim lives at an unprecedented rate and has caused a devastating range of preventable morbidity. Although the availability of highly potent synthetic opioids has amplified the urgency of the crisis for patients and communities, this problem has evolved over several decades. Pharmacists are in a position to offer many potential solutions due to their widespread accessibility, extensive drug knowledge, and integration into various health care settings. This opinion paper challenges the status quo by calling on all pharmacists to embrace evidence‐based opioid stewardship and harm reduction practices, contribute to the medical management of opioid use disorder, and address the misconceptions and prejudices that serve as barriers to effective, compassionate patient care. Regardless of practice setting or available resources, pharmacists can take deliberate and impactful steps to address the opioid crisis. Some pharmacists may be positioned to implement innovative and far‐reaching pharmacist‐led clinical services, while others may simply begin with careful consideration of the language they use when speaking to and about patients with substance use disorders. To optimize patient outcomes, the ineffective laws, regulations, and policies that negatively impact pain and addiction care must be addressed so that evidence‐based solutions can be widely disseminated. Pharmacists must aggressively advocate for the removal of barriers preventing high‐level clinical practice or policies that perpetuate patient harm and abandonment. Finally, there must be support for continued research on pain and opioid use disorder treatments and services, as well as the impacts of harm reduction practices and pharmacist‐led clinical services, so that resources can be allocated effectively.